---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-002018"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2022-02-08T23:59:59+00:00"
generated_at: "2026-06-27T10:05:59.120712+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics CMO H. Jeffrey Wilkins resigns; effective date TBD

## Summary
- Dr. Wilkins resigns as Chief Medical Officer effective upon a date to be agreed upon.
- He will assist in orderly transition of duties through the effective date.
- No replacement named in the filing.

## SEC filing metadata
- accession: 0001628280-22-002018
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2022-02-08T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828022002018/0001628280-22-002018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828022002018/avtx-20220202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-002018
- JSON: https://secwatch.observer/filing/0001628280-22-002018.json
- Plain text: https://secwatch.observer/filing/0001628280-22-002018.txt

## Key facts
- Executive change
  H. Jeffrey Wilkins resigned as Chief Medical Officer at Avalo Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On February 2, 2022, H. Jeffrey Wilkins resigned as Chief Medical Officer of Avalo Therapeutics, Inc., to be effective upon a date to be agreed upon.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828022002018/0001628280-22-002018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.